EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Understanding and Treating Hepatorenal Syndrome: Insights from Recent Research

Yuli Song, Xiaochen Yang, Chengbo Yu

Seminars in Liver Disease · 01.09.2025 · 45 (03) · 328-347

DOI: 10.1055/a-2570-3330 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Liver Disease, erschienen am 01.09.2025. Verfasst von Yuli Song und 2 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Inn…. Hauptthemen laut MEDLINE: Hepatorenal Syndrome, Liver Cirrhosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 93 Literaturangaben. Gefördert von: The National Nature Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute kidney injury (AKI) is a critical and often fatal complication in decompensated cirrhosis, significantly affecting inpatient survival rates. Hepatorenal syndrome (HRS), a distinct subtype of AKI, develops in individuals with advanced cirrhosis and portal hypertension. It is marked by progressive kidney dysfunction, poor prognosis, and frequently causes death before liver transplantation. The pathogenesis of HRS involves vasodilation of the splanchnic vessels, leading to overactivation of the endogenous vasoactive systems, circulatory dysfunction, and reduced renal perfusion, which ultimately impairs glomerular filtration. Recent studies have highlighted the role of systemic inflammation in exacerbating renal damage. Despite these changes, renal histology in HRS usually shows no significant abnormalities, and there is typically no hematuria, proteinuria, or abnormal findings on ultrasound. Common risk factors for HRS include spontaneous bacterial peritonitis, infections, and large-volume paracentesis without albumin infusion. Diagnosing HRS is challenging, particularly in distinguishing it from acute tubular necrosis, due to the absence of specific biomarkers. Treatment primarily involves vasoconstrictors such as terlipressin and albumin, with liver transplantation being the definitive therapeutic option. This review provides an updated understanding of HRS, addressing its pathophysiology, diagnosis, management, and future challenges, based on recent expert consensus.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatorenal SyndromeLiver CirrhosisHumansLiver TransplantationVasoconstrictor AgentsRisk Factors

Substanzen

Vasoconstrictor Agents

Autor:innen und Institutionen

  • State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The…

Förderung

  • The National Nature Science Foundation of China

Zitieren

APA

Song, Y., Yang, X., & Yu, C. (2025). Understanding and Treating Hepatorenal Syndrome: Insights from Recent Research. Seminars in Liver Disease, 45(03), 328-347. https://doi.org/10.1055/a-2570-3330

Vancouver

Song Y, Yang X, Yu C. Understanding and Treating Hepatorenal Syndrome: Insights from Recent Research. Seminars in Liver Disease. 2025;45(03):328-347. doi:10.1055/a-2570-3330

BibTeX
@article{Song2025,
  author = {Song, Yuli and Yang, Xiaochen and Yu, Chengbo},
  title = {Understanding and Treating Hepatorenal Syndrome: Insights from Recent Research},
  journal = {Seminars in Liver Disease},
  year = {2025},
  volume = {45},
  number = {03},
  pages = {328--347},
  doi = {10.1055/a-2570-3330}
}
Kostenlos starten →